Canada to approve VNT Selective Herbicide

Health Canada's Pest Management Regulatory Agency (PMRA), under the authority of the Pest Control Products Act, is proposing registration for the sale and use of Intelligro IBA Technical, containing the technical grade active ingredient indole-3-butyric acid, Intelligro Calcium Disodium EDTA Technical, containing the technical grade active ingredient calcium disodium ethylenediaminetetraacetic acid (EDTA) hydrate, the manufacturing concentrate VNT MFG and the end-use product VNT Selective Herbicide Ready-to-Use, containing the technical grade active ingredients indole-3-butyric acid and calcium disodium EDTA hydrate for control of broadleaf weeds and moss on turf.

Indole-3-butyric acid (IBA) is a naturally occurring auxin, which is a plant hormone. IBA primarily promotes lateral/adventitious root formation in the plants. When IBA is administered to plants at higher concentrations, it causes uncontrolled cell division and abnormal growth, which may lead to death of susceptible plants.

Calcium disodium EDTA hydrate (CaNa2 EDTA) is a chelating agent, which may act both as a penetrant to improve uptake of IBA and to counteract the destruction of IBA during auxin conjugation and transport in the plant cells.

VNT Selective Herbicide provides control, suppression, or partial suppression of several broadleaf weeds and moss on residential lawns.

VNT Selective Herbicide, containing 1.25% IBA and 2% CaNa2 EDTA, is formulated as a ready-to-use product for spot treatment on lawns. Application of VNT Selective Herbicide provides control, suppression, or partial suppression of numerous broadleaf weeds and moss.

VNT Selective Herbicide is a non-conventional herbicide that will serve as an alternative option for broadleaf weed and moss management on residential lawns.

Before making a final registration decision on indole-3-butyric acid, calcium disodium EDTA hydrate, VNT MFG and VNT Selective Herbicide Ready-to-Use, Health Canada's PMRA will consider any comments received from the public in response to PRD2021-01. Health Canada will accept written comments on PRD2021-01 up to 45 days from the date of publication of PRD2021-01 (from 5 March 2021 to 19 April 2021).